Latest News & Features
Biotechnology
Should it be possible for a drug maker to stop the owner of a patented ingredient from obtaining an SPC? Ashley Roughton examines the CJEU’s opinion on Eli Lilly v HGS. 29 October 2014
Americas
In the competitive world of cancer treatment it’s becoming ever more important to stand out from the crowd. LSIPR speaks to TapImmune’s chief executive Glynn Wilson on why he thinks the company does. 29 October 2014
Americas
Earlier this month, the first LSIPR roundtable discussion took place in a London hotel, chaired by managing editor Martin Essex, with six invited experts and deputy editor
Ed Conlon taking part. We’ll be publishing a special report on the event but, to whet your appetite, here’s how the discussion began—with a lively debate on the USPTO’s guidelines on patent-eligible subject matter in the wake of the Myriad and Mayo court decisions. 30 September 2014
Americas
The Bay Area of California has one
of the greatest concentrations of life
sciences companies in the world,
but its biotech community is being
threatened by the seemingly
unstoppable rise of large technology businesses. LSIPR spoke to Christopher Stewart, chair, and Robert Eyler,
vice chair, of the new North Bay
Life Science Alliance to find out
how it plans to strengthen the network in the area. 30 September 2014
Big Pharma
Increasing numbers of patent challengers are finding the USPTO’s post-grant procedures to be attractive alternatives to district court litigation, write Arlene Chow and Peter Noh. 29 September 2014
Americas
Sifting through the published comments on the USPTO’s Myriad/Mayo guidelines, LSIPR found them to be overwhelmingly negative. 4 September 2014
Genetics
Pluristem develops therapies using cells from the placenta that have been cultured in a unique way. LSIPR finds out how the company protects and nourishes its technologies. 4 September 2014
Big Pharma
For those who can draw an informative patent map and work out a good navigational route through the complexities, there is an opportunity to gain significant competitive advantages through making the right partnerships, argue Quentin Tannock and Anna Duch. 4 September 2014
Big Pharma
Parties need to take care when considering interim injunctions and keep an eye on future IP litigation, says Jan Lindberg. 1 August 2014
article
The development of gene technologies is still at a relatively early stage, with patent applications coming from research institutes and universities as well as industry. Gareth Williams has crunched the numbers. 1 August 2014